First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival ...

An online platform may help increase access to and reduce barriers associated with germline testing for individuals with cancer, according to findings presented at ASCO Annual Meeting.An analysis of ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Scientists at St. Jude Children's Research Hospital have found that genetics and type of cancer treatment contribute most to ...

And here’s the kicker: Every extra kilo (2.2 pounds) at birth over “normal” birth weight — that’s 2.5 to 4 kilograms, or 5.51 ...

Despite how far we’ve come in our awareness of hereditary cancer risk, some people have no firsthand experience with this health challenge — or what to say when discussing it — and that’s ...

1 Génétique Oncologique EPHE, INSERM U753, Institut de cancérologie Gustave Roussy Villejuif; and Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France 2 Service de Génétique, Institut de ...

An otherwise active, healthy 39-year-old, Marisa Peters was a mother of three boys and still nursing her 16-month-old when she was initially diagnosed with Stage 3 rectal cancer.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Environmental factors such as lifestyle and the medications you take influence the effects your genes have on your body — and can clarify how diseases develop.